BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One 2020;15:e0232283. [PMID: 32343721 DOI: 10.1371/journal.pone.0232283] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022;76:1880-97. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
2 Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, Ćwiertnia M, Hajduga MB. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives. Cancers 2022;14:5811. [DOI: 10.3390/cancers14235811] [Reference Citation Analysis]
3 Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H, Kawaguchi T. Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol 2022. [PMID: 36131166 DOI: 10.1007/s00795-022-00334-9] [Reference Citation Analysis]
4 Hendryx M, Dong Y, Ndeke JM, Luo J. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE 2022;17:e0274519. [DOI: 10.1371/journal.pone.0274519] [Reference Citation Analysis]
5 Sasaki-Tanaka R, Shibata T, Moriyama M, Okamoto H, Kogure H, Kanda T. Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy. J Virol 2022;:e0064622. [PMID: 36040176 DOI: 10.1128/jvi.00646-22] [Reference Citation Analysis]
6 Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 2022. [PMID: 36039537 DOI: 10.1002/hep4.2069] [Reference Citation Analysis]
7 Zügner E, Yang H, Kotzbeck P, Boulgaropoulos B, Sourij H, Hagvall S, Elmore CS, Esterline R, Moosmang S, Oscarsson J, Pieber TR, Peng X, Magnes C. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. IJMS 2022;23:7966. [DOI: 10.3390/ijms23147966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nakano D, Kawaguchi T, Tsutsumi T, Hayakawa M, Yoshio S, Koga H, Torimura T. Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells. JGH Open. [DOI: 10.1002/jgh3.12730] [Reference Citation Analysis]
10 Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review. Rev Endocr Metab Disord 2021. [PMID: 34272645 DOI: 10.1007/s11154-021-09675-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hoerner CR, Miao SY, Hsieh JJ, Fan AC. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities. Cancer J 2020;26:407-18. [PMID: 32947309 DOI: 10.1097/PPO.0000000000000472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]